Company registration number NI035059 (Northern Ireland)
MD HEALTHCARE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
MD HEALTHCARE LIMITED
COMPANY INFORMATION
Directors
Mr D A Dunlop
Dr P Megarity
Mrs L Megarity
Mr D Doherty
Secretary
Dr P Megarity
Company number
NI035059
Registered office
Movilla House
2 Berkshire Road
Newtownards
Down
BT23 7HH
Auditor
HM Chartered Accountants
6th Floor East Tower
Lanyon Plaza
8 Lanyon Place
Belfast
Co. Antrim
BT1 3LP
Bankers
Ulster Bank Limited
22 Frances Street
Newtownards
BT23 7DP
MD HEALTHCARE LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2 - 3
Independent auditor's report
4 - 7
Income statement
8
Group statement of comprehensive income
9
Group statement of financial position
10
Company statement of financial position
11
Group statement of changes in equity
12
Company statement of changes in equity
13
Group statement of cash flows
14
Notes to the financial statements
15 - 31
MD HEALTHCARE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 1 -

The directors present the strategic report for the year ended 31 October 2025.

Review of the business

The directors consider the results for the year to be satisfactory. The group will continue to seek every opportunity to increase profitable turnover.

Principal risks and uncertainties

Performance in the sector is affected by general economic conditions. The board carries out regular strategic reviews including assessment of competitor activity and market trends. The security of service supply is monitored by the directors on an ongoing basis with product quality and service levels regularly reviewed. The group's active review of market prices both provides protection and maximises opportunities from anticipated price risks.

Key performance indicators

Given the straightforward nature of the business, the group's directors are of the opinion that analysis using KPIs is not necessary for an understanding of the development, performance or position of the business.

On behalf of the board

Dr P Megarity
Director
30 June 2026
MD HEALTHCARE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 2 -

The directors present their annual report and financial statements for the year ended 31 October 2025.

Principal activities

The principal activity of the company and group is the provision of nursing care services.

Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £142,408. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr D A Dunlop
Dr P Megarity
Mrs L Megarity
Mr D Doherty
Disabled persons

Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.

Employee involvement

The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.

 

Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.

 

There is no employee share scheme at present, but the directors are considering the introduction of such a scheme as a means of further encouraging the involvement of employees in the company's performance.

Auditor

In accordance with the company's articles, a resolution proposing that be reappointed as auditor of the group will be put at a General Meeting.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

United Kingdom company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.

MD HEALTHCARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 3 -

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

On behalf of the board
Dr P Megarity
Director
30 June 2026
MD HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MD HEALTHCARE LIMITED
- 4 -
Opinion

We have audited the financial statements of MD Healthcare Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 October 2025 which comprise the group income statement, the group statement of comprehensive income, the group statement of financial position, the company statement of financial position, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

MD HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF MD HEALTHCARE LIMITED
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

MD HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF MD HEALTHCARE LIMITED
- 6 -

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

We focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including Companies Act 2006, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation

We assessed the susceptibility of the company’s financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

To address the risk of fraud through management bias and override of controls, we:

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

agreeing financial statement disclosures to underlying supporting documentation;

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

MD HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF MD HEALTHCARE LIMITED
- 7 -

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Angela Craigan (Senior Statutory Auditor)
For and on behalf of HM Chartered Accountants, Statutory Auditors
Chartered Accountants
6th Floor East Tower
Lanyon Plaza
8 Lanyon Place
Belfast
Co. Antrim
BT1 3LP
30 June 2026
MD HEALTHCARE LIMITED
GROUP INCOME STATEMENT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 8 -
2025
2024
Notes
£
£
Turnover
3
11,635,186
10,673,516
Cost of sales
(158,699)
(146,282)
Gross profit
11,476,487
10,527,234
Administrative expenses
(10,862,538)
(10,156,156)
Other operating income
22,549
62,351
Operating profit
5
636,498
433,429
Interest receivable and similar income
6
3,200
3,254
Interest payable and similar expenses
7
(163,054)
(192,762)
Profit before taxation
476,644
243,921
Tax on profit
8
(183,535)
(124,049)
Profit for the financial year
23
293,109
119,872
Profit for the financial year is all attributable to the owners of the parent company.
MD HEALTHCARE LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 OCTOBER 2025
- 9 -
2025
2024
£
£
Profit for the year
293,109
119,872
Other comprehensive income
-
-
Cash flow hedges gain arising in the year
-
0
-
0
Total comprehensive income for the year
293,109
119,872
Total comprehensive income for the year is all attributable to the owners of the parent company.
MD HEALTHCARE LIMITED
GROUP STATEMENT OF FINANCIAL POSITION
AS AT
31 OCTOBER 2025
31 October 2025
- 10 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
10
158,208
348,055
Tangible assets
11
4,206,710
4,267,403
4,364,918
4,615,458
Current assets
Stocks
14
22,132
31,599
Debtors
16
492,493
487,648
Cash at bank and in hand
535,961
700,563
1,050,586
1,219,810
Creditors: amounts falling due within one year
17
(1,604,730)
(1,914,379)
Net current liabilities
(554,144)
(694,569)
Total assets less current liabilities
3,810,774
3,920,889
Creditors: amounts falling due after more than one year
18
(1,843,815)
(2,106,766)
Provisions for liabilities
Deferred tax liability
20
109,906
107,772
(109,906)
(107,772)
Net assets
1,857,053
1,706,351
Capital and reserves
Called up share capital
22
300,000
300,000
Profit and loss reserves
23
1,557,053
1,406,351
Total equity
1,857,053
1,706,351

These financial statements have been prepared in accordance with the provisions relating to medium-sized groups.

The financial statements were approved by the board of directors and authorised for issue on 30 June 2026 and are signed on its behalf by:
30 June 2026
Mr D A Dunlop
Dr P Megarity
Director
Director
Company registration number NI035059 (Northern Ireland)
MD HEALTHCARE LIMITED
COMPANY STATEMENT OF FINANCIAL POSITION
AS AT 31 OCTOBER 2025
31 October 2025
- 11 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
11
3,689,455
3,719,213
Investments
12
1,846,846
1,846,846
5,536,301
5,566,059
Current assets
Stocks
14
15,368
18,620
Debtors
16
475,801
622,697
Cash at bank and in hand
290,592
387,130
781,761
1,028,447
Creditors: amounts falling due within one year
17
(1,372,076)
(1,685,790)
Net current liabilities
(590,315)
(657,343)
Total assets less current liabilities
4,945,986
4,908,716
Creditors: amounts falling due after more than one year
18
(1,843,815)
(2,106,766)
Provisions for liabilities
Deferred tax liability
20
89,030
83,566
(89,030)
(83,566)
Net assets
3,013,141
2,718,384
Capital and reserves
Called up share capital
22
300,000
300,000
Profit and loss reserves
23
2,713,141
2,418,384
Total equity
3,013,141
2,718,384

As permitted by section 408 of the Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £437,165 (2024 - £295,537 profit).

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 30 June 2026 and are signed on its behalf by:
30 June 2026
Mr D A Dunlop
Dr P Megarity
Director
Director
Company registration number NI035059 (Northern Ireland)
MD HEALTHCARE LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2025
- 12 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 November 2023
300,000
1,428,886
1,728,886
Year ended 31 October 2024:
Profit and total comprehensive income
-
119,872
119,872
Dividends
9
-
(142,408)
(142,408)
Balance at 31 October 2024
300,000
1,406,351
1,706,351
Year ended 31 October 2025:
Profit and total comprehensive income
-
293,109
293,109
Dividends
9
-
(142,408)
(142,408)
Balance at 31 October 2025
300,000
1,557,053
1,857,053
MD HEALTHCARE LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2025
- 13 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 November 2023
300,000
2,265,255
2,565,255
Year ended 31 October 2024:
Profit and total comprehensive income for the year
-
295,537
295,537
Dividends
9
-
(142,408)
(142,408)
Balance at 31 October 2024
300,000
2,418,384
2,718,384
Year ended 31 October 2025:
Profit and total comprehensive income
-
437,165
437,165
Dividends
9
-
(142,408)
(142,408)
Balance at 31 October 2025
300,000
2,713,141
3,013,141
MD HEALTHCARE LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 14 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
26
578,161
977,627
Interest paid
(163,054)
(192,762)
Income taxes paid
(115,102)
(2)
Net cash inflow from operating activities
300,005
784,863
Investing activities
Purchase of intangible assets
-
(517,914)
Purchase of tangible fixed assets
(116,344)
(128,500)
Interest received
3,200
3,254
Net cash used in investing activities
(113,144)
(643,160)
Financing activities
Repayment of borrowings
-
(9,588)
Repayment of bank loans
(209,052)
1,633,621
Dividends paid to equity shareholders
(142,408)
(142,408)
Net cash (used in)/generated from financing activities
(351,460)
1,481,625
Net (decrease)/increase in cash and cash equivalents
(164,599)
1,623,328
Cash and cash equivalents at beginning of year
700,563
788,114
Cash and cash equivalents at end of year
535,961
700,563
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 15 -
1
Accounting policies
Company information

MD Healthcare Limited (“the company”) is a private limited company domiciled and incorporated in Northern Ireland. The registered office is Movilla House, 2 Berkshire Road, Newtownards, BT23 7HH.

 

The group consists of MD Healthcare Limited and all of its subsidiaries.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 16 -
1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company MD Healthcare Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 October 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.

Investments in joint ventures and associates are carried in the group statement of financial position at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.

 

If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.

 

Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.

1.4
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the group and parent company have adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 17 -
1.6
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 5-7 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.7
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
1% and 2% straight line
Plant and equipment
20% straight line
Fixtures and fittings
25% reducing balance
Computers
33.33% reducing balance
Motor vehicles
15% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income statement.

1.8
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 18 -

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

 

Investments in associates are initially recognised at the transaction price (including transaction costs) and are subsequently adjusted to reflect the group’s share of the profit or loss, other comprehensive income and equity of the associate using the equity method. Any difference between the cost of acquisition and the share of the fair value of the net identifiable assets of the associate on acquisition is recognised as goodwill. Any unamortised balance of goodwill is included in the carrying value of the investment in associates.

 

Losses in excess of the carrying amount of an investment in an associate are recorded as a provision only when the company has incurred legal or constructive obligations or has made payments on behalf of the associate.

 

In the parent company financial statements, investments in associates are accounted for at cost less impairment.

Entities in which the group has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.9
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.10
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 19 -

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.11
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.12
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's statement of financial position when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 20 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.13
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 21 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.17
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.18
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 22 -
2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Useful lives of tangible fixed assets

Long-lived assets comprising primarily of property, plant and machinery represent a significant portion of total assets. The annual depreciation charge depends primarily on the estimated lives of each type of asset and, in certain circumstances, estimates of residual values. The directors regularly review these useful lives and change them if necessary to reflect current conditions. In determining these useful lives management consider technological change, patterns of consumption, physical condition and expected economic utilisation of the assets. Changes in the useful lives can have a significant impact on the depreciation charge for the financial year. The net book value of tangible fixed assets subject to depreciation at the financial year end date was £4,206,710 (2024: £4,267,403).

3
Turnover and other revenue

All of the group's turnover is generated from activities being that of nursing care services, and, is derived in the United Kingdom.

2025
2024
£
£
Other revenue
Interest income
3,200
3,254
Grants received
-
60,074
4
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
331
324
264
252
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
4
Employees
(Continued)
- 23 -

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
8,468,088
7,760,686
6,542,174
5,981,414
Pension costs
166,956
153,788
131,551
121,586
8,635,044
7,914,474
6,673,725
6,103,000
5
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging/(crediting):
Government grants
-
(60,074)
Depreciation of owned tangible fixed assets
177,039
171,849
Amortisation of intangible assets
189,847
189,847
6
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
3,173
3,254
Other interest income
27
-
Total income
3,200
3,254
2025
2024
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
3,173
3,254
7
Interest payable and similar expenses
2025
2024
£
£
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
818
743
Other interest on financial liabilities
162,236
192,019
163,054
192,762
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 24 -
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
181,401
115,123
Deferred tax
Other adjustments
2,134
8,926
Total tax charge
183,535
124,049

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
476,644
243,921
Expected tax charge based on the standard rate of corporation tax in the UK of 25% (2024: 25%)
119,161
60,980
Effects of:
Unutilised tax losses carried forward
-
0
(6,787)
Accelerated capital allowances
2,477
(2,978)
Permanent differences
61,777
62,060
Timing Defferences
(2,014)
1,849
Deferred Tax
2,134
8,925
Taxation charge in the financial statements
183,535
124,049
9
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Interim paid
142,408
142,408
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 25 -
10
Intangible fixed assets
Group
Goodwill
£
Cost
At 1 November 2024 and 31 October 2025
1,403,189
Amortisation and impairment
At 1 November 2024
1,055,134
Amortisation charged for the year
189,847
At 31 October 2025
1,244,981
Carrying amount
At 31 October 2025
158,208
At 31 October 2024
348,055
Company
Goodwill
£
Cost
At 1 November 2024 and 31 October 2025
74,257
Amortisation and impairment
At 1 November 2024 and 31 October 2025
74,257
Carrying amount
At 31 October 2025
-
0
At 31 October 2024
-
0
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 26 -
11
Tangible fixed assets
Group
Freehold land and buildings
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 November 2024
4,800,075
535,109
1,492,717
103,543
204,447
7,135,891
Additions
-
0
8,771
87,055
15,820
4,698
116,344
Disposals
-
0
-
0
(884,101)
(4,231)
(16,043)
(904,375)
At 31 October 2025
4,800,075
543,880
695,670
115,133
193,102
6,347,860
Depreciation and impairment
At 1 November 2024
996,361
420,084
1,238,731
76,682
136,630
2,868,488
Depreciation charged in the year
54,635
26,777
72,149
10,534
12,944
177,039
Eliminated in respect of disposals
-
0
-
0
(884,101)
(4,231)
(16,043)
(904,375)
At 31 October 2025
1,050,997
446,858
426,780
82,985
133,530
2,141,150
Carrying amount
At 31 October 2025
3,749,078
97,022
268,890
32,148
59,572
4,206,710
At 31 October 2024
3,803,714
115,025
253,986
26,861
67,817
4,267,403
Company
Freehold land and buildings
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 November 2024
3,911,259
1,492,716
80,027
204,447
5,688,449
Additions
-
0
87,055
12,718
4,698
104,471
Disposals
-
0
(884,101)
(4,231)
(16,043)
(904,375)
At 31 October 2025
3,911,259
695,670
88,514
193,102
4,888,545
Depreciation and impairment
At 1 November 2024
540,710
1,238,732
53,165
136,629
1,969,236
Depreciation charged in the year
39,113
72,149
10,023
12,944
134,229
Eliminated in respect of disposals
-
0
(884,101)
(4,231)
(16,043)
(904,375)
At 31 October 2025
579,823
426,780
58,957
133,530
1,199,090
Carrying amount
At 31 October 2025
3,331,436
268,890
29,557
59,572
3,689,455
At 31 October 2024
3,370,549
253,985
26,861
67,818
3,719,213
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 27 -
12
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
13
-
0
-
0
1,846,846
1,846,846
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 November 2024 and 31 October 2025
1,846,846
Carrying amount
At 31 October 2025
1,846,846
At 31 October 2024
1,846,846
13
Subsidiaries

Details of the company's subsidiaries at 31 October 2025 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Ashdon Care Limited
Northern Ireland
Nursing care services
Ordinary
100.00
14
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Raw materials and consumables
22,132
31,599
15,368
18,620
15
Financial instruments
Group
Company
2025
2024
2025
2024
£
£
£
£
Carrying amount of financial assets
Debt instruments measured at amortised cost
178,254
174,582
215,525
382,446
Carrying amount of financial liabilities
Measured at amortised cost
3,267,171
3,809,752
3,114,381
3,640,089
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 28 -
16
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
151,493
166,048
151,067
162,671
Amounts owed by group undertakings
-
0
-
0
40,431
211,941
Other debtors
224,183
205,956
190,990
174,797
Prepayments and accrued income
116,817
115,644
93,313
73,288
492,493
487,648
475,801
622,697
17
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans
19
364,001
310,104
364,001
310,104
Trade creditors
643,760
547,051
611,022
510,729
Corporation tax payable
181,374
115,075
101,510
56,149
Other taxation and social security
-
0
96,318
-
0
96,318
Other creditors
110,057
565,937
107,721
542,387
Accruals and deferred income
305,538
279,894
187,822
170,103
1,604,730
1,914,379
1,372,076
1,685,790
18
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
19
1,843,815
2,106,766
1,843,815
2,106,766
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 29 -
19
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Bank loans
2,207,816
2,416,870
2,207,816
2,416,870
Payable within one year
364,001
310,104
364,001
310,104
Payable after one year
1,843,815
2,106,766
1,843,815
2,106,766

The long-term loans are secured by fixed charges over the assets of the company, including debentures, Freehold 1st Legal Charges, Leasehold 1st Legal Charge and an Inter Company Guarantee.

 

20
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company:

Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
112,070
111,950
Timing differences
(2,164)
(4,178)
109,906
107,772
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
91,194
87,744
Timing differences
(2,164)
(4,178)
89,030
83,566
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 November 2024
107,772
83,566
Charge to profit or loss
2,134
5,464
Liability at 31 October 2025
109,906
89,030
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
20
Deferred taxation
(Continued)
- 30 -

The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.

21
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
166,956
153,788

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

22
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of £1 each
75,000
75,000
75,000
75,000
Ordinary B shares of £1 each
75,000
75,000
75,000
75,000
Ordinary C shares of £1 each
75,000
75,000
75,000
75,000
Ordinary D shares of £1 each
75,000
75,000
75,000
75,000
300,000
300,000
300,000
300,000
MD HEALTHCARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 31 -
23
Reserves
Profit and loss reserves

The profit and loss reserve represents cumulative profits or losses.

 

24
Directors' transactions

Dividends totalling £106,806 (2024 - £106,806) were paid in the year in respect of shares held by the company's directors.

25
Analysis of changes in net debt - group
1 November 2024
Cash flows
31 October 2025
£
£
£
Cash at bank and in hand
700,563
(164,602)
535,961
Borrowings excluding overdrafts
(2,416,870)
209,054
(2,207,816)
(1,716,307)
44,452
(1,671,855)
26
Cash generated from group operations
2025
2024
£
£
Profit for the year after tax
293,109
119,872
Adjustments for:
Taxation charged
183,535
124,049
Finance costs
163,054
192,762
Investment income
(3,200)
(3,254)
Amortisation and impairment of intangible assets
189,847
189,847
Depreciation and impairment of tangible fixed assets
177,039
171,849
Movements in working capital:
Decrease/(increase) in stocks
9,467
(754)
Increase in debtors
(4,845)
(68,474)
(Decrease)/increase in creditors
(429,845)
261,444
Cash generated from operations
578,160
987,340
2025-10-312024-11-01falsefalseCCH SoftwareCCH Accounts Production 2026.200Mr D A DunlopMrs L MegarityMr D DohertyMr D DohertyDr P MegarityfalseNI035059bus:Consolidated2024-11-012025-10-31NI0350592024-11-012025-10-31NI035059bus:Director12024-11-012025-10-31NI035059bus:CompanySecretaryDirector12024-11-012025-10-31NI035059bus:Director22024-11-012025-10-31NI035059bus:Director32024-11-012025-10-31NI035059bus:CompanySecretary12024-11-012025-10-31NI035059bus:Director42024-11-012025-10-31NI035059bus:RegisteredOffice2024-11-012025-10-31NI035059bus:Agent12024-11-012025-10-31NI0350592025-10-31NI035059bus:Agent1bus:Consolidated2024-11-012025-10-31NI035059bus:Consolidated2025-10-31NI035059bus:Consolidated2023-11-012024-10-31NI0350592023-11-012024-10-31NI035059core:Goodwillbus:Consolidated2025-10-31NI035059core:Goodwillbus:Consolidated2024-10-31NI035059core:Goodwill2025-10-31NI035059core:Goodwill2024-10-31NI035059bus:Consolidated2024-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-10-31NI035059core:PlantMachinerybus:Consolidated2025-10-31NI035059core:FurnitureFittingsbus:Consolidated2025-10-31NI035059core:ComputerEquipmentbus:Consolidated2025-10-31NI035059core:MotorVehiclesbus:Consolidated2025-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-10-31NI035059core:PlantMachinerybus:Consolidated2024-10-31NI035059core:FurnitureFittingsbus:Consolidated2024-10-31NI035059core:ComputerEquipmentbus:Consolidated2024-10-31NI035059core:MotorVehiclesbus:Consolidated2024-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssets2025-10-31NI035059core:FurnitureFittings2025-10-31NI035059core:ComputerEquipment2025-10-31NI035059core:MotorVehicles2025-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-31NI035059core:FurnitureFittings2024-10-31NI035059core:ComputerEquipment2024-10-31NI035059core:MotorVehicles2024-10-31NI0350592024-10-31NI035059core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-10-31NI035059core:CurrentFinancialInstrumentsbus:Consolidated2024-10-31NI035059core:ShareCapitalbus:Consolidated2025-10-31NI035059core:ShareCapitalbus:Consolidated2024-10-31NI035059core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-10-31NI035059core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-10-31NI035059core:ShareCapital2025-10-31NI035059core:ShareCapital2024-10-31NI035059core:RetainedEarningsAccumulatedLosses2025-10-31NI035059core:RetainedEarningsAccumulatedLosses2024-10-31NI035059core:ShareCapitalbus:Consolidated2023-10-31NI035059core:ShareCapital2023-10-31NI035059core:RetainedEarningsAccumulatedLosses2023-10-31NI035059core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-31NI035059core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-31NI035059core:Non-currentFinancialInstrumentscore:AfterOneYear2025-10-31NI035059core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-31NI035059core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-10-31NI035059core:Goodwill2024-11-012025-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssets2024-11-012025-10-31NI035059core:PlantMachinery2024-11-012025-10-31NI035059core:FurnitureFittings2024-11-012025-10-31NI035059core:ComputerEquipment2024-11-012025-10-31NI035059core:MotorVehicles2024-11-012025-10-31NI035059core:UKTaxbus:Consolidated2024-11-012025-10-31NI035059core:UKTaxbus:Consolidated2023-11-012024-10-31NI035059bus:Consolidated12024-11-012025-10-31NI035059bus:Consolidated12023-11-012024-10-31NI035059bus:Consolidated22024-11-012025-10-31NI035059bus:Consolidated22023-11-012024-10-31NI035059bus:Consolidated32024-11-012025-10-31NI035059bus:Consolidated32023-11-012024-10-31NI035059core:Goodwillbus:Consolidated2024-10-31NI035059core:Goodwill2024-10-31NI035059core:Goodwillbus:Consolidated2024-11-012025-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-10-31NI035059core:PlantMachinerybus:Consolidated2024-10-31NI035059core:MotorVehiclesbus:Consolidated2024-10-31NI035059bus:Consolidated2024-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-31NI035059core:FurnitureFittings2024-10-31NI035059core:ComputerEquipment2024-10-31NI035059core:MotorVehicles2024-10-31NI0350592024-10-31NI035059core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-11-012025-10-31NI035059core:PlantMachinerybus:Consolidated2024-11-012025-10-31NI035059core:FurnitureFittingsbus:Consolidated2024-11-012025-10-31NI035059core:ComputerEquipmentbus:Consolidated2024-11-012025-10-31NI035059core:MotorVehiclesbus:Consolidated2024-11-012025-10-31NI035059core:ComputerEquipmentbus:Consolidated2024-10-31NI035059core:Subsidiary12024-11-012025-10-31NI035059core:Subsidiary112024-11-012025-10-31NI035059core:CurrentFinancialInstrumentsbus:Consolidated2025-10-31NI035059core:CurrentFinancialInstruments2025-10-31NI035059core:CurrentFinancialInstruments2024-10-31NI035059core:CurrentFinancialInstrumentsbus:Consolidated12025-10-31NI035059core:CurrentFinancialInstrumentsbus:Consolidated12024-10-31NI035059core:CurrentFinancialInstruments22025-10-31NI035059core:CurrentFinancialInstruments22024-10-31NI035059core:WithinOneYearbus:Consolidated2025-10-31NI035059core:WithinOneYearbus:Consolidated2024-10-31NI035059core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2025-10-31NI035059core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-10-31NI035059bus:PrivateLimitedCompanyLtd2024-11-012025-10-31NI035059bus:FRS1022024-11-012025-10-31NI035059bus:Audited2024-11-012025-10-31NI035059bus:ConsolidatedGroupCompanyAccounts2024-11-012025-10-31NI035059bus:FullAccounts2024-11-012025-10-31xbrli:purexbrli:sharesiso4217:GBP